Skip to content
DataLookout
Menu

NCT06709326

APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Identify circulating tumor cells (CTC) for molecular characterization
Timeframe: At inclusion in the study and after 4 weeks of treatment.
Differentiated gene expression in CTCs before and after treatment start
Timeframe: At inclusion in the study and after 4 weeks of treatment.
Phenotypical changes of immune cells due to anti-androgen treatment
Timeframe: At inclusion in the study, after 4 weeks of treatment, after 3, 6 and 12 months of treatment.

Secondary (1)

Progression free survival

Arms and interventions

Primary metastatic prostate cancerExperimental

Men who have not previously received treatment for prostate cancer.

PSA relapseExperimental

Men with PSA recurrance after surgery.

Healthy research subjectsOther

Control group to distinguish tumor-specific changes from normal signals.

Diagnostic tests: Apheresis, Anti androgen therapy

Other: Androgen deprivation therapy

Sites

1 site in 1 country

  • Department of surgical and perioperative sciences, Umeå universityUmeå, Norrlands University Hospital, Sweden